Annex

QUESTIONNAIRE FOR THE TESTING OF THE GUIDANCE ON RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

GENERAL INFORMATION ABOUT THE TESTING								
Q1. These results are being submitted on behalf of a:	☐ Party. Please specify: Thailand							
	☐ Other Government. Please specify: <country's name=""></country's>							
	☐ Organization: Please specify: <organization's name=""></organization's>							
Q2. When was the testing of the Guidance conducted?	Please enter date: 17 November 2011							
Q3. Type of event where the testing of the Guidance was conducted?	Group event (e.g., workshop, training course, meeting). Please provide the title of the event and name of organizer: Plant Biosafety Subcommittee							
	Type of meeting:							
	Online							
	Individual exercise. Please provide your name, occupation and affiliation: Dr. Kanutcharee Thainispong, government officer, Bureau of Vector Borne Disease; Department of Disease Control							
		Other: Please specify: <type here=""></type>						
Q4. Which sections of the Guidance were tested?	\boxtimes	Part I: The Roadmap for Risk assessment of LMOs						
	Part II: Specific types of LMOs or Traits:							
	Risk assessment of LMOs with stacked genes or traits							
	Risk assessment of LM crops with tolerance to abiotic stress							
		☐ Risk assessment of LM mosquitoes						
OVERALL EVALUATION								
			Very poor	Poor	Neutral	Good	Very good	
Please indicate the level of agreement you a	ttribute	to each of i	the questions	in the left col	lumn.			
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?								
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in <u>a scientifically sound and case-by-case manner</u> ?						\boxtimes		
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs introduced into various receiving environments?					\boxtimes			

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.					
Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>			
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	⊠ Yes □ No	Comments: <type here=""></type>			
Q10. Is the Roadmap organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>			
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>			
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	☐ Yes ☑ No	Comments: <type here=""></type>			
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	☐ Yes ⊠ No	Comments: <type here=""></type>			
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	☐ Yes ⊠ No	Comments: In regarding to the receiving environment, the intended scale and duration of the environmental release should be clearly indicated.			
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	⊠ Yes □ No	Comments: <type here=""></type>			

PART II: SPECIFIC TYPES OF LIVING MODIFIED ORGANISMS OR TRAITS

Risk assessment of living modified organisms with stacked genes or traits

Kisk assessment of fiving mounted organisms with stacked genes of traits						
Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.						
Q16. Does this section provide useful guidance when conducting risk assessments of LMOs with stacked genes or traits in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>				
Q17. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LMOs with stacked genes of traits?	⊠ Yes □ No	Comments: <type here=""></type>				
Q18. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>				
Q19. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>				
Q20. Is there any other issue or concept that you would like to see included in this section of the Guidance?	☐ Yes ⊠ No	Comments: <type here=""></type>				
Risk assessment of living modified crops with tolerance to abiotic stress						
Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.						
Q21. Does this section provide useful guidance when conducting risk assessments of LM crops with tolerance to abiotic stress(es) in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>				
Q22. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LM crops with tolerance to abiotic stress(es)?	⊠ Yes □ No	Comments: <type here=""></type>				
Q23. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>				
Q24. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>				
Q25. Is there any other issue or concept that you would like to see included in this section of the Guidance?	⊠ Yes □ No	Comments: In the last 2 lines of page 18: "Would the abiotic stress tolerance trait, for example, via pleitropic effects, have the potential to affect, inter alia, pest and disease resistance mechanisms of the LM crop?" it difficult to understand./ is the term "abioteic stress" include the meaning of herbicide tolerance?				

Risk assessment of living modified mosquitoes						
Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.						
Q26. Does this section provide useful guidance when conducting risk assessments of LM mosquitoes in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>				
Q27. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LM mosquitoes?	⊠ Yes	Comments: <type here=""></type>				
Q28. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>				
Q29. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>				
Q30. Is there any other issue or concept that you would like to see included in this section of the Guidance?	☐ Yes ⊠ No	Comments: <type here=""></type>				

ADDITIONAL COMMENTS

Please add any additional comment you may have regarding the "Guidance on Risk Assessment of Living Modified Organisms" below.

Q31. This Roadmap provides further guidance which can be useful as a reference for risk assessors when conducting or reviewing risk assessments. However, LMOs of different taxa would need to be evaluated differently.
